Author

A. A. Antolin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 3 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

B. Al-Lazikani· 2 shared M. Ameratunga· 2 shared P. Workman· 2 shared A. Llebaria· 1 shared C. Serra· 1 shared D. M. Thomas· 1 shared F. P. Lin· 1 shared F. Y. Zaman· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

B. Al-Lazikani

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Computational repurposing of oncology drugs through off-target drug binding interactions from pharmacological databases

I. R. Walpole, F. Y. Zaman, P. Zhao, V. M. Marshall, F. P. Lin, D. M. Thomas, M. Shackleton, A. A. Antolin, M. Ameratunga

This paper presents a computational method to identify off-target drug binding interactions for oncology drug repurposing using pharmacological databases and clinical data.

bioRxiv · Jul 1, 2023Biochemistry

Identification of differential polypharmacology between the PARP inhibitor rucaparib and its major metabolite

H. Hu, C. Serra, A. Llebaria, A. A. Antolin

This study identifies differential polypharmacology between rucaparib and its metabolite M324, showing distinct kinase inhibition profiles with potential clinical implications.

bioRxiv · Nov 22, 2022 · PreprintPharmacology & Toxicology

Evolution of kinase polypharmacology across HSP90 drug discovery

A. A. Antolin, P. A. Clarke, I. Collins, P. Workman, B. Al-Lazikani

This study systematically characterizes the kinase cross-pharmacology of HSP90 inhibitors and shows that polypharmacology evolved during drug optimization.

bioRxiv · Sep 9, 2020Pharmacology & Toxicology

The off-target kinase landscape of clinical PARP inhibitors

A. A. Antolin, M. Ameratunga, U. Banerji, P. Clarke, P. Workman, B. Al-Lazikani

This study identifies the off-target kinase profiles of four FDA-approved PARP inhibitors, revealing unique polypharmacological effects with potential clinical implications.

bioRxiv · Jan 14, 2019Pharmacology & Toxicology